159 related articles for article (PubMed ID: 7923563)
21. The proteasome inhibitor PS-341 in cancer therapy.
Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J
Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643
[TBL] [Abstract][Full Text] [Related]
22. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
23. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
24. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
Teicher BA; Holden SA; Ara G; Northey D
Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
[TBL] [Abstract][Full Text] [Related]
25. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher BA; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
In Vivo; 1997; 11(4):301-11. PubMed ID: 9292296
[TBL] [Abstract][Full Text] [Related]
26. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS
Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897
[TBL] [Abstract][Full Text] [Related]
27. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
28. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Teicher BA; Korbut TT; Menon K; Holden SA; Ara G
Cancer Chemother Pharmacol; 1994; 33(6):515-22. PubMed ID: 8137463
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
[TBL] [Abstract][Full Text] [Related]
31. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
[TBL] [Abstract][Full Text] [Related]
32. A preclinical model for sequential high-dose chemotherapy.
Holden SA; Teicher BA; Ayash LJ; Frei E
Cancer Chemother Pharmacol; 1995; 36(1):61-4. PubMed ID: 7720177
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
[TBL] [Abstract][Full Text] [Related]
34. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Ayash L; Korbut T; Herman TS; Teicher BA
Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
[TBL] [Abstract][Full Text] [Related]
35. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
36. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Teicher BA; Holden SA; Khandakar V; Herman TS
J Cancer Res Clin Oncol; 1993; 119(11):645-51. PubMed ID: 8394365
[TBL] [Abstract][Full Text] [Related]
37. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase inhibitors - invitro and invivo effects on antitumor alkylating-agents in the emt-6 murine mammary-carcinoma.
Teicher B; Holden S; Ara G; Liu J; Robinson M; Flodgren P; Dupuis N; Northey D
Int J Oncol; 1993 Feb; 2(2):145-53. PubMed ID: 21573528
[TBL] [Abstract][Full Text] [Related]
39. The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors.
Wietrzyk J; Opolski A; Madej J; Radzikowski C
Acta Pol Pharm; 2000 Nov; 57 Suppl():5-8. PubMed ID: 11293263
[TBL] [Abstract][Full Text] [Related]
40. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]